Christopher Gannatti and Aneeka Gupta make the case for why disciplined capital management and structural tailwinds are driving the WisdomTree Efficient Gold Plus Gold Miners Strategy Fund (GDMN)’s ...

Behnood Noei explains how the WisdomTree U.S. Short Term Corporate Bond Fund (QSIG) targets high-quality U.S. corporates with a rules-based process, earning top rankings while keeping risk in check.

The Federal Reserve held rates steady for the fifth consecutive meeting, with policy makers remaining in wait-and-see mode. Rising political pressure and tariff uncertainties have created a complex ...

In a recent newsletter, we explored the explosive growth of ETFs and the implications for portfolio construction. In this follow-up blog post, Lauren and I wanted to take that conversation a step ...

The dual-market system behind ETFs, primary and secondary markets, enables intraday liquidity and tight pricing spreads that distinguish them from mutual funds. Authorized participants play a critical ...

In 2025, high-tech logistics is transforming into the economic infrastructure of immediacy, with robotic fulfillment systems redefining efficiency and throughput across supply chains. Despite ...

There's a tectonic shift unfolding in global finance—subtle in appearance, but profound in implication. The traditional signposts of market anxiety—stocks, bonds, even crypto—are being bypassed in ...

Christopher Gannatti explores how agentic AI is evolving from task-specific tools to autonomous systems capable of real-world decision-making, and what this means for investors navigating the next ...

Market volatility seems ever present, and with a historically negative correlation to equities, the U.S. dollar has emerged as a powerful yet often overlooked portfolio diversifier.

On a recent episode of the Basis Points podcast, Kevin Flanagan spoke with Morgan Stanley’s Vishwanath Tirupattur to break down the competitive landscape, expected returns and why both private credit ...

With Treasury yields likely to stay elevated, Kevin Flanagan and Sam Rines discuss why investors should prepare for continued volatility and consider a strategic fixed income approach to navigate the ...

After years of underwhelming performance, biotech may finally be ready for a breakthrough in 2025. Chris Gannatti highlights how advancements in gene editing, AI-driven drug discovery and policy ...